Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
This trial is active, not recruiting.
|Conditions||advanced adult primary liver cancer, liver metastases, localized unresectable adult primary liver cancer, recurrent adult primary liver cancer|
|Treatments||positron emission tomography, computed tomography|
|Sponsor||Ohio State University Comprehensive Cancer Center|
|Start date||January 2014|
|End date||July 2015|
|Trial size||60 participants|
|Trial identifier||NCT02119065, NCI-2014-00278, OSU-13176|
This pilot clinical trial studies positron emission tomography (PET)/computed tomography (CT) in finding beads after Yttrium-90 bead therapy in patients with primary liver cancer or cancer that has spread to the liver (metastatic) that can not be removed by surgery. Imaging procedures, such as PET/CT after Yttrium-90 bead therapy, may help see if the beads are present in the lung and compare the results with the pre-therapy imaging.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
Absolute difference in post-therapy Yttrium-90 microsphere and pre-therapy Technetium-99m macroaggregated albumin hepatopulmonary shunt fraction values
time frame: Baseline to up to 36 hours after radioembolization
In vitro Technetium-99m macroaggregated albumin particle size and microsphere size for each patient
time frame: Baseline up to 24 months
Male or female participants at least 18 years old.
Inclusion Criteria: - Patients who undergo intra-arterial hepatic 99mTc MAA evaluation in anticipation of 90Y microsphere radioembolization Exclusion Criteria: - Patients who are unable to give consent - Prisoners
|Official title||PET/CT-Derived Hepatopulmonary Shunt Fraction Following Yttrium-90 Radioembolization|
|Principal investigator||Chadwick Wright|
|Description||PRIMARY OBJECTIVES: I. To estimate the absolute difference in post-therapy Yttrium-90 microsphere hepatopulmonary shunt fraction and the pre-therapy Technetium-99m macroaggregated albumin hepatopulmonary shunt fraction in patients with unresectable primary hepatic malignancy and hepatic metastatic disease. SECONDARY OBJECTIVES: I. To quantify and compare the pre-therapy Technetium-99m macroaggregated albumin particle sizes and post-therapy Yttrium-90 microsphere sizes. OUTLINE: Patients receive routine pre-therapy Technetium-99m macroaggregated albumin. Patients then undergo routine radioembolization with Yttrium-90 microspheres. Within 36 hours after radioembolization, patients undergo PET/CT imaging. Available imaging, clinical, interventional and surgical follow-up data for 2 years after completion of enrollment in the study will be obtained.|
Call for more information